Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
Items 301–400 of 808
Blondeau, J. M., Charles, M., Loo, V. G., Adam, H. J., Vecchio, M. G.-D., Ghakis, C., O’Callaghan, E., & Ali, R. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-40012-z · Cited by 6
Long Story Short: Establishing Breakpoints for Antimicrobials and 2023 Updates
Bixby, M. L., Zheng, D., & Hirsch, E. B. (2024) · Current Infectious Disease Reports · doi:10.1007/s11908-024-00830-2 · Cited by 6
Wang, J., Lai, C., Tsai, Y., Ko, W., & Hsueh, P. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107105 · Cited by 6
Sardari, M., Manouchehrifar, M., Hasani, K., Habibzadeh, N., Doghaheh, H. P., Azimi, T., & Arzanlou, M. (2024) · Journal of Water and Health · doi:10.2166/wh.2024.321 · Cited by 6
Long, H., Zhao, F., Feng, Y., & Zong, Z. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107141 · Cited by 6
Gopalakrishnan, R., Sethuraman, N., Nambi, S., Ramanathan, Y. V., Chandran, C., Vineeth, V. K., & Ramasubramanian, V. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24709 · Cited by 6
“15,16 This is however critically dependent on the exact enzyme produced by the organism and carries important implications for individual patient outcome and antimicrobial stewardship.”
BackgroundMaeda, M., Sunaga, T., Sato, M. T., Hasegawa, T., Noma, H., & Ota, E. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.05.001 · Cited by 8
Pérez-Viso, B., Martins-Oliveira, I., Gomes, R., Silva-Dias, A., Peixe, L. M. S. V., Novais, Â., Pina‐Vaz, C., & Cantón, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147888 · Cited by 6
“…Discrepant results (*) comparing flow cytometry with our phenotypic reference method and PCR molecular testing were reported in four isolates (Table 3). carbapenemase screening (meropenem MIC ˃ 0.125 mg/L) recommended by the European Committee of Antimicrobial Susceptibility Testing (EUCAST) [14].”
BackgroundMethodInfluentialWang, Z., Ye, L., Fu, P., Wu, X., Xu, J., Ye, Y., Han, S., Wang, C., & Yu, H. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1408959 · Cited by 6
Chew, K. L., Tan, K. X., Bakar, N. A. B. A., Lin, R. T. P., & Teo, J. W. P. (2025) · Pathology · doi:10.1016/j.pathol.2024.12.647 · Cited by 6
Olivet, J., Amerson-Brown, M. H., Calix, J. J., Graffice, E., Kilpatrick, T., Roenfanz, H. F., Nicolau, D. P., Kuti, J. L., & Brown, M. L. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70019 · Cited by 6
“5,6 Furthermore, tazobactam effectively inhibits many AmpC and extended- spectrum-β - lactamases (ESBLs); however, this beta-lactamase inhibitor generally adds little to the activity of ceftolozane for MDR or DTR P. aeruginosa isolates.”
Iosifidis, Ε., & Bradley, J. S. (2023) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004124 · Cited by 6
Riccobene, T. A., Ai, C., Yu, K. C., Gregory, S., Kim, B., Debabov, D. V., & Gupta, V. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03129-23 · Cited by 6
Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023
Rodriguez-Leal, C., González‐Corralejo, C., Candel, F. J., & Salavert, M. (2024) · Revista Española de Quimioterapia · doi:10.37201/req/018.2024 · Cited by 9
“Table 10 shows the differences between the recommendations for treatment of A. baumannii Carbapenems Resistant (CR) provided by IDSA and ESCMID [163,177,178].”
BackgroundMethodSharma, D., Sulaiman, Z. I., Tu, P. J., Harrell, S., Cavalieri, S., Skidmore, P. J., & Baer, S. L. (2024) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096241239544 · Cited by 6
“7 Although various enteric organisms, including some Citrobacter species, may possess the ability to produce AmpC , clinical relevance may be insignificant due to low overall B-lactamase production, even in the presence of inducing agents; C koseri does not appear to have chromosomally encoded AmpC…”
BackgroundEmpirical antimicrobials in the intensive care unit
Bus, L. D., Arvaniti, K., & Sjövall, F. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07453-0 · Cited by 8
“1) [10].”
Tilley, M. S., Edwards, S., Brown, M. L., Li, P., Mehta, S. G., Walker, J. B., & Gutierrez, K. C. (2024) · Clinical Transplantation · doi:10.1111/ctr.15390 · Cited by 5
Wong, O., Mezcord, V., Lopez, C., Traglia, G. M., Pasterán, F. G., Tuttobene, M. R., Corso, A. C., Tolmasky, M. E., Bonomo, R. A., & Ramirez, M. S. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00930-24 · Cited by 5
Self-citationSoriano, À., Paterson, D. L., Thalhammer, F., Kluge, S., Viale, P., Akrich, B., Allen, M., Wirbel, S., Watanabe, A. H., Yücel, E., et al. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.116737 · Cited by 5
Yu, W., Zhang, H., Xu, Y., Zhu, Y., Jia, P., Kang, Y., & Yang, Q. (2025) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2025.02.001 · Cited by 5
Doernberg, S. B., Heil, E. L., Fiawoo, S., Lee, J. H., Cosgrove, S. E., Dobrzynski, D., Li, Y., Shields, R. K., Spivak, E. S., Stohs, E. J., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70160 · Cited by 5
Self-citationde Souza, P. A., dos Santos, M. C. S., de Miranda, R. V. D. S. L., da Costa, L. V., da Silva, R. P. P., Silva, C., Midlej, V. D. V. P., de Miranda, C. A. C., da Conceição, G. M. S., Forsythe, S. J., et al. (2025) · Brazilian Journal of Microbiology · doi:10.1007/s42770-025-01669-y · Cited by 5
Biswal, D., Chawla, A., Kumari, P., Mangla, S., & Salhotra, R. (2025) · Journal of Critical Care · doi:10.1016/j.jcrc.2025.155207 · Cited by 5
Central Line–Associated Bloodstream Infections in Pediatrics: A Review
Bavare, A. C., Foster, C. E., Wollam, A. L., & Campbell, J. R. (2025) · Pediatrics in Review · doi:10.1542/pir.2024-006506 · Cited by 5
Canada’s 2025 AMR priority pathogens: Evidence-based ranking and public health implications
Abdesselam, K., Ngendabanka, R.-J., Muchaal, P. K., Amaratunga, K., Mishra, A., Narkar, R., Crago, A.-L., & Lary, T. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330128 · Cited by 7
Ghannam, I. A., Owdetallah, S. R., Al‐Khatib, S. M., Zboun, D. I., Alhelale, E. A., Najjar, K. A., & Ghannam, Y. I. (2025) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-025-01652-0 · Cited by 5
“…(MDR) organisms were defined as those resistant to at least one agent in three or more antimicrobial classes, while extensively drug-resistant (XDR) organisms were defined as those susceptible to only one or two antimicrobial classes, in accordance with WHO and CDC guidelines [13, 14].”
Xu, K., Wu, D., Zeng, C.-J., Guo, J., Xi, D.-Y., Wang, M., Yao, Z., Feng, A.-Q., Ji, F., Yan, X., et al. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i42.112478 · Cited by 5
“Enterobacterales producing ESBL primarily exhibit resistance to third-generation cephalosporins and aztreonam, whereas carbapenem-resistant strains display resistance against carbapenems including meropenem, imipenem, and ertapenem[9,10].”
Złotowska, A., Buzun, W. H., Pełka, K., Zalewska, Z., & Duszyńska, W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238415 · Cited by 5
“However, in monotherapy they are only recommended for the treatment of UTIs with CRE etiology [152].”
VanDorf, S., Shah, P., & Yost, C. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231205219 · Cited by 5
Namiki, T., Yokoyama, Y., Hashi, H., Oda, R., Jibiki, A., Kawazoe, H., Matsumoto, K., Suzuki, S., & Nakamura, T. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2894 · Cited by 5
“3 However, it has been reported that carbapenem-resistant Enterobacterales are prevalent with increased carbapenem use.”
BackgroundGatti, M., Rinaldi, M., Tonetti, T., Siniscalchi, A., Viale, P., & Pea, F. (2024) · Antibiotics · doi:10.3390/antibiotics13040296 · Cited by 5
Urinary Tract Infection in Male Patients
Drekonja, D. M. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.03.009 · Cited by 5
Serwacki, P., Hareza, D. A., Kujawska, A., Pałka, A., Jachowicz-Matczak, E., Rybka-Grymek, A., Kwapniewska, W. Ś. –., Pawłowska, I., Gniadek, Z., Gutkowska, K., et al. (2024) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16734 · Cited by 5
Paukner, S., Kimber, S., Cumper, C., Rea-Davies, T., Ballesteros, L. S., Kirkham, C. M., Hargreaves, A., Gelone, S. P., Richards, C., & Wicha, W. W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105401 · Cited by 5
“For the treatment of bacterial pneumonia, the focus of therapy has mainly been on the reduction in the bacterial burden by the mandatory use of effective antibiotics [13].”
BackgroundYou, T.-Y., Lo, C.-L., Tsai, W.-C., Jan, H.-E., Ko, W., & Lee, N. (2024) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2024.05.010 · Cited by 5
A review on drug resistance patho-mechanisms in ESKAPE bacterial pathogens
Jain, A., Oli, A. K., Kulkarni, S. S., Kulkarni, R. D., & Chandrakanth, R. K. (2024) · Novel Research in Microbiology Journal · doi:10.21608/nrmj.2024.287047.1549 · Cited by 5
Contreras-Valero, J. F., Gualtero-Trujillo, S. M., Cortés, G., Hernández-Garzón, S., Manrique-Marín, N., Narváez-Chaves, M. Á., & Valderrama, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33698 · Cited by 5
“Although there is a growing body of literature guiding the therapeutic approach of infections caused by KPC-or metallobetalactamase-producing CRE, the absence of recommendations and trials for infections with carbapenemase co-producing strains is still a major evidence gap [27].”
Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs
Ghosh, M., Iarikov, D. E., Qi, X. (., Rubin, D., Shurland, S. M., Goodwin, A., Wei, X., Chilukuri, D., McMaster, O., Miller, T. J., et al. (2024) · Emerging infectious diseases · doi:10.3201/eid3011.231416 · Cited by 5
“However, current treatment guidelines acknowledge that no clear standard-of-care regimen exists for the treatment of CR ABC infections ( 8 ).”
BackgroundSutton, S. P., & Reinert, J. P. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241291604 · Cited by 5
Shi, J., Gao, J., Zhu, Y., Zhao, C., Wang, W., Chen, S., & Yao, Q. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116659 · Cited by 5
Pharmacokinetic Changes and Influencing Factors of Polymyxin B in Different ECMO Modes
Xu, M., Chen, N., Yu, Y., Pan, X.-Y., & Li, T. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s486169 · Cited by 5
“7 As the prevalence of carbapenem-resistant gram-negative organisms has increased, polymyxins have re-entered clinical consideration and become the first-line treatment for these infections.”
Geremia, N., Bella, S. D., Lovecchio, A., Angelini, J., D’Avolio, A., Luzzati, R., Mearelli, F., Principe, L., & Oliva, A. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2448727 · Cited by 5
Walker, M. K., Chishti, E. A., Yek, C., Sarzynski, S. H., Angelo, S., Cohn, J., Livinski, A. A., & Kadri, S. S. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.02.029 · Cited by 5
Webb, A. R., Fernandez, A., & Piccicacco, N. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70048 · Cited by 5
Ferrara, F., Martellone, L., Vaccaro, M., Coluccia, A., Scognamiglio, M., Langella, R., Zovi, A., & Polito, G. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03866-y · Cited by 5
Nekidy, W. S. E., Abdel-Salam, M., Nusair, A. R., Lababidi, R. E., Dajani, R. Z., John, T. J. L. S., & Ghazi, I. M. (2021) · Hospital Pharmacy · doi:10.1177/00185787211066460 · Cited by 5
Aminoglycoside Therapeutic Drug Monitoring: On Paper vs in Practice
Narayanan, N., & Lewis, J. S. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad446 · Cited by 5
Jeon, C.-H., Kim, S., Kim, H., Park, K., & Wi, Y. M. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.03.007 · Cited by 5
Massol, J., Dinh, A., Jeannot, K., Duran, C., Bouchand, F., Potron, A., Dortet, L., & Jehl, F. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.05.014 · Cited by 6
Shalabi, O., Kashat, L., Murik, O., Zevin, S., Assous, M. V., & Ben‐Chetrit, E. (2024) · Antibiotics · doi:10.3390/antibiotics13080709 · Cited by 5
Gatti, M., Cosentino, F., Giannella, M., Viale, P., & Pea, F. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107168 · Cited by 5
Cefepime–Taniborbactam in Complicated Urinary Tract Infection
Lanini, S., Cai, T., & Tascini, C. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2403590 · Cited by 5
Wang, L., Xu, C., Si, L., Gan, G., Lin, B., & Yu, Y. (2024) · Critical Care · doi:10.1186/s13054-024-05111-x · Cited by 5
Sherman, E. R., Ta, N. H., Branan, T. N., Patimavirujh, N., Dickinson, L. A., Bland, C. M., & Smith, S. E. (2024) · Antibiotics · doi:10.3390/antibiotics13100921 · Cited by 4
Jung, J., Park, H., Oh, S., Choi, J., An, S., Jeong, Y., Kim, J., Baek, Y. J., Lee, E., & Kim, T. H. (2024) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-024-01495-1 · Cited by 5
“The therapeutic options for CRE infections are limited, and there is a growing concern about resistance to newly developed beta-lactam and beta-lactamase inhibitor combinations that constitute the primary treatment recommended in the guidelines of the Infectious Diseases Society of America [2, 3].”
Huang, T., Luo, Y., Wu, Y. Y., Niu, L., Xiao, Y., Wu, T., Chen, X., Liu, Y., Lu, J., Zhu, D., et al. (2025) · Science Progress · doi:10.1177/00368504251325334 · Cited by 4
“40,41 However, this study is subject to certain limitations.”
Chiusaroli, L., Tripiciano, C., Liberati, C., Pieri, M. D., Brigadoi, G., & Donà, D. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2519690 · Cited by 4
“Fosfomycin is currently recommended for the treatment of uncomplicated lower urinary tract infections (uUTIs) caused by ESBL and carbapenem-resistant Escherichia coli in children of all ages [14].”
InfluentialAlzaidi, S., Alharthi, M., Alshammamri, H., Al-Malki, Y., Almalki, O., Alqahtani, S., Alosaimi, M., & Althumali, N. (2025) · IDCases · doi:10.1016/j.idcr.2025.e02296 · Cited by 4
Morales-Domínguez, C., Oueslati, S., Laham, N. A., Nermont, R., Volland, H., & Naas, T. (2025) · Microorganisms · doi:10.3390/microorganisms13092140 · Cited by 4
“The CAZ/AVI combination has since become a first-line treatment option for MDR bacterial infections and is recommended by several infectious disease societies for infections caused by bacteria harboring KPC and OXA-48 carbapenemases [32,33].”
Dai, A., Zheng, F., Liu, J., Chen, Q., Zhou, Z., Yu, L., Yu, Z., & Guan, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s553622 · Cited by 4
Tao, J., Wang, L., Yang, N., Fu, H., Hu, X., Lai, T., Jin, J., & Li, G. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1683102 · Cited by 4
Xiao, Y., Zhang, G., Nie, F., Li, P., Li, K., Tao, X., Zheng, F., Zhao, R., & Zhang, W. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.12.011 · Cited by 4
Sirago, G., Rollo, E., Zotti, F., Solarino, B., Dell'Erba, A. S., & Ferorelli, D. (2025) · Journal of Patient Safety · doi:10.1097/pts.0000000000001450 · Cited by 4
Burn Infections and Sepsis: Challenges and Future Prospects of Antibacterial Therapy
Dadashizadeh, G., Elloso, M. S., & Jeschke, M. G. (2026) · Antibiotics · doi:10.3390/antibiotics15040383 · Cited by 4
Abi Manesh, S., Aslan, A. T., George, M. M., Sulaiman, H., Huttner, A., Mathers, A. J., Zavascki, A. P., Mo, Y., Yahav, D., Rando, E., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag025 · Cited by 4
Self-citationMikita, K., Tajima, M., Haque, A., Kato, Y., Iwata, S., Suzuki, K., Hasegawa, N., Yano, H., & Matsumoto, T. (2024) · Diagnostics · doi:10.3390/diagnostics14101027 · Cited by 4
“Currently carbapenemase genotypic testing is performed at relatively few institutes, but such testing should be expanded to evaluate most, if not all, clinical samples to optimize treatments and maximize control [8].”
BackgroundCefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak
Travi, G., Peracchi, F., Merli, M., Re, N. L., Matarazzo, E., Tartaglione, L., Bielli, A., Casalicchio, G., Crippa, F., Vismara, C., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13080770 · Cited by 4
“Current guidelines suggest the use of sulbactam as a first line treatment for carbapenem-resistant A. baumannii (CRAB), which have no activity against MBL-producing strains [9,10].”
BackgroundInfluentialAñón-Hidalgo, J., Garrido-Rodríguez, M., González-Abad, M. J., Vendrell, M. C., García‐Ascaso, M. T., Pérez, D. D., & García‐Salido, A. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116539 · Cited by 4
Amikacin treatment in patients with Enterobacterales bacteraemia: impact of MIC on mortality
Zohar, I., David, D. B., Schwartz, O., Pomerantz, A., Caliari, G., Hoffman, E., & Maor, . (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae343 · Cited by 4
Midlick, D., Harhay, J., & Summers, N. A. (2024) · Access Microbiology · doi:10.1099/acmi.0.000852.v4 · Cited by 4
“It is to be noted that per the 2023 Infectious Diseases Society of America Antimicrobial Resistance guidance, the recommended treatment options for CRE-identified complicated UTI (cUTI) is ceftazidime–avibactam, meropenem–vaborbactam, imipenem–cilastatin–relebactam or cefiderocol [11].”
BackgroundFouad, A., Nicolau, S. E., Tamma, P. D., Simner, P. J., Nicolau, D. P., & Gill, C. M. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae346 · Cited by 5
Self-citationErtapenem in the Context of Hypoalbuminemia: Implications for Critically Ill Patients
Seazzu, M., & Cabanilla, M. G. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70011 · Cited by 4
Dallasheh, H., & Paul, M. (2025) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2025.04.006 · Cited by 4
Cia, C.-T., Su, S.-L., Tsai, P.-F., Su, Y.-C., Lee, N., Ko, W., & Chen, P. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00234-25 · Cited by 4
Dezza, F. C., Navarro, P. O., Caponcello, M. G., Salazar-Moscoso, M., Pérez, P. C., Retamar, P., González, I. A., Oteo-Iglesias, J., Torre-Cisneros, J., Horcajada, J. P., et al. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.103033 · Cited by 4
Cortés, J. A., Leal, A. L., Muñetón-López, G., Bravo-Ojeda, J. S., Nócua-Báez, L. C., Ávila, V., Silva, E., Álvarez, C., Espitia, P., Gualtero, S. M., et al. (2021) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v69n3.90140 · Cited by 4
How to treat severe Acinetobacter baumannii infections
Bouza, E., Muñóz, P., & Burillo, A. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000974 · Cited by 5
Gatti, M., Bonazzetti, C., Pascale, R., Giannella, M., Viale, P., & Pea, F. (2024) · Microorganisms · doi:10.3390/microorganisms12010151 · Cited by 4
“…a large debate still exists nowadays about which therapeutic choices should be preferred in this scenario [7–12], as argued both in the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines and in the Infectious Diseases Society of America (IDSA) guidance [13,14].”
Özenen, G. G., Bal, Z. Ş., Bolat, E., Ümit, Z., Bilen, N. M., Arslan, S. Y., Turhan, T., Çilli, F., & Kurugöl, Z. (2024) · Journal of Neurosurgery Pediatrics · doi:10.3171/2024.1.peds23363 · Cited by 4
Jaber, A. M. R. A., Başgut, B., Hawan, A. A., Shehri, A. A. A., Alkahtani, S. A., Ahmed, N. J., & Abdi, A. M. (2024) · Antibiotics · doi:10.3390/antibiotics13030265 · Cited by 4
“Microbial eradication was defined as obtaining two consecutive negative cultures from the same and/or different sites [45].”
BackgroundMethodInfluentialSümer, Ş., Azap, Ö. K., Aygün, G., Akalın, H., Akova, M., & Köksal, İ. (2024) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.2024011051 · Cited by 4
“Ayrıca sefiderokol, MBL varlığında kullanılabilecek bir diğer antibiyotiktir ve henüz ülkemizde bulunmamaktadır [38,74] .”
BackgroundInfluentialAlmangour, T. A., Ghonem, L., Alassiri, D., Aljurbua, A., Musawa, M. A., Alharbi, A., Almuhisen, S., Alghaith, J., Damfu, N., Aljefri, D. M., et al. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.03.015 · Cited by 4
Sun, K., Peng, F., Xu, K., Liu, Y., Zhou, X., Shang, N., & Li, C. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1385118 · Cited by 5
Soman, R. N., Veeraraghavan, B., Hegde, A. V., Varma, S., Todi, S. K., Singh, R. K., Nagavekar, V., Rodrigues, C. S., Swaminathan, S., Ramsubramanian, V., et al. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2360116 · Cited by 4
Carbapenem-resistant Enterobacterales in wastewater resources and healthy carriers: A survey in Iran
khavandi, S., Habibzadeh, N., Hasani, K., Sardari, M., & Arzanlou, M. (2024) · Journal of Water and Health · doi:10.2166/wh.2024.041 · Cited by 4
Yee, L. J. K. G., Abad, C. L. R., Cabaluna, I. T. G., & Lim, J. A. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116481 · Cited by 4
Viasus, D., Gudiol, C., & Carratalà, J. (2024) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001190 · Cited by 5
Afonso, L., Grzegorczyk, K. G., Salomão, J. M., Basso, K. R., Alves, L. C., Silva, M. C. R., Chryssafidis, A. L., Cano, B. G., Yamada‐Ogatta, S. F., & Andrade, G. (2024) · Antibiotics · doi:10.3390/antibiotics13090875 · Cited by 4
“…susceptible to FlpC, such as KPC-producing K. µ (MIC = 0.5 µ g 1 µ 1 vancomycin-resistant E. faecium VRE-170 ( 1 The last recommends the or ampicillin–sulbactam (a saturation of sulbactam) for CRAB treatment, all used in combination therapy regimens with at least one more antimicrobial agent [37].”
BackgroundInfluentialKaki, R. (2024) · Access Microbiology · doi:10.1099/acmi.0.000826.v4 · Cited by 4
“To date, there is no standard treatment for CRAB, but the general consensus is to combine high-dose ampicillin–sulbactam along with another antimicrobial agent, such as minocycline, colistin, polymyxin B, cefiderocol or tigecycline [62].”
BackgroundBuonomo, A. R., Scotto, R., Esposito, N. D. P., Viceconte, G., Moriello, N. S., Zumbo, G., Vecchietti, I., Lanzardo, A., Iacovazzo, C., Curcio, F., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13111007 · Cited by 4
Almangour, T. A., Alkherb, Z., Ghonem, L., Musawa, M. A., Almohaizeie, A., Almuhisen, S., Alharbi, A., Damfu, N., Aljefri, D. M., Alghaith, J., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18010108 · Cited by 4
“The term “difficult-to-treat” resistance (DTR) was introduced earlier [25], and is currently used in the latest Infectious Diseases Society of America guidance [26].”
Thomas, C., Peterson, J., Ahiskali, A., Hamid, L., Butts, J. F., Czachura, J., & Alpern, J. D. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.08.007 · Cited by 4
Radha, S., Warrier, A. R., Wilson, A., & Prakash, S. (2023) · Cureus · doi:10.7759/cureus.33623 · Cited by 4
Al-Zubairy, S. A. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s411381 · Cited by 4
Pandey, S., Yao, P., Qian, Z., Ji, T., Wang, K., & Gao, L. (2023) · Interdisciplinary Neurosurgery · doi:10.1016/j.inat.2023.101832 · Cited by 4
Nosocomial pneumonia: Current etiology and impact on antimicrobial therapy
Rio, J. J. G.-D., Candel, F. J., & del Castillo, J. M. G. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/s01.03.2023 · Cited by 4
“…pneumonia have not been revised since 2016, in recent years, several scientific societies have formulated anti-microbial treatment recommendations for addressing infections caused by resistant gram-negative bacteria, particularly for invasive infections involving P. aeruginosa [12,28-30].”
BackgroundArns, B., Horvath, J. D. C., Rech, G. S., Sesin, G. P., Agani, C. A. J. O., da Rosa, B. S., dos Santos, T. M., Brochier, L. S. B., Cavalcanti, A. B., Tomazini, B. M., et al. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00897-9 · Cited by 5
“For example, polymyxins and aminoglycosides are no longer recommended therapy for carbapenem-resistant Enterobacterales [22, 23], but they are still used in some resource-limited centers.”
Tsai, Y. V., Bookstaver, P. B., Kohn, J. E., Justo, J. A., Childress, D. T., Stramel, S., Slain, D., Tu, P. J., Wingler, M. J. B., Jones, B. M., et al. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2024.26 · Cited by 4
“13 In addition, although the prevalence of DTR Acinetobacter spp. approached 20% toward the end of the study period, Acinetobacter spp. represented only a small fraction of total GNB in this study.”
BackgroundSurge of Mpox Cases in Lombardy Region, Italy, October 2023—January 2024
Moschese, D., Raccagni, A. R., Giacomelli, A., Piralla, A., Rossotti, R., Raimondi, A., Tesoro, D., Vezzosi, L., Gulletta, M., Clementi, N., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae184 · Cited by 4
Du, N., You, D., Tenzing, D., Qu, D., Meng, J., Wang, Y., & He, J. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s468413 · Cited by 4
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.